NCT02393794View on ClinicalTrials.gov

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 17, 2015

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Triple-Negative Breast CancerBreast Cancer
Interventions
DRUG

Romidepsin

Histone deacetylase inhibitor

DRUG

Cisplatin

Platinum compound

DRUG

Nivolumab

Monoclonal antibody, checkpoint inhibitor

Trial Locations (7)

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64131

University of Kansas Cancer Center - South, Kansas City

64154

University of Kansas Cancer Center - North, Kansas City

66112

University of Kansas Cancer Center - West, Kansas City

66205

University of Kansas Cancer Center - Clinical Research Center, Fairway

University of Kansas Cancer Center - Westwood, Westwood

66210

University of Kansas Cancer Center - Overland Park, Overland Park

Sponsors

Lead Sponsor

Priyanka Sharma
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Priyanka Sharma

OTHER